Cancer biology in diabetes update: Focusing on antidiabetic drugs

被引：1

作者：

Kawakita, Emi ^{[1
]}

Kanasaki, Keizo ^{[1
,2
]}

机构：

[1] Shimane Univ, Fac Med, Dept Internal Med 1, Izumo, Japan

[2] Shimane Univ, Fac Med, Ctr Integrated Kidney Res & Adv, Izumo, Japan

来源：

JOURNAL OF DIABETES INVESTIGATION | 2024年 / 15卷 / 05期

基金：

日本学术振兴会;

关键词：

Antidiabetic drugs; Cancer; Diabetes; GLUCAGON-LIKE PEPTIDE-1; RANDOMIZED PHASE-II; ACTING INSULIN ANALOGS; ALL-CAUSE MORTALITY; BLADDER-CANCER; COLORECTAL-CANCER; CARDIOVASCULAR OUTCOMES; PANCREATIC-CANCER; BREAST-CANCER; PIOGLITAZONE USE;

D O I：

10.1111/jdi.14152

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The association of type 2 diabetes with certain cancer risk has been of great interest for years. However, the effect of diabetic medications on cancer development is not fully understood. Prospective clinical trials have not elucidated the long-term influence of hypoglycemic drugs on cancer incidence and the safety for cancer-bearing patients with diabetes, whereas numerous preclinical studies have shown that antidiabetic drugs could have an impact on carcinogenesis processes beyond the glycemic control effect. Because there is no evidence of the safety profile of antidiabetic agents on cancer biology, careful consideration would be required when prescribing any medicines to patients with diabetes and existing tumor. In this review, we discuss the potential influence of each diabetes therapy in cancer 'initiation', 'promotion' and 'progression'. The long-term influence of antidiabetic drugs use on cancer biology is not fully elucidated. We summarize and discuss the potential influence of each diabetes therapy in cancer 'initiation', 'promotion' and 'progression'. image

引用

页码：525 / 540

页数：16

共 187 条

[31] Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group [J].

Colhoun, H. M. .

DIABETOLOGIA, 2009, 52 (09) :1755-1765

[32] Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis [J].

Colmers, I. N. ;

Bowker, S. L. ;

Johnson, J. A. .

DIABETES & METABOLISM, 2012, 38 (06) :475-484

[33] Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis [J].

Coyle, C. ;

Cafferty, F. H. ;

Vale, C. ;

Langley, R. E. .

ANNALS OF ONCOLOGY, 2016, 27 (12) :2184-2195

[34] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes [J].

Currie, C. J. ;

Poole, C. D. ;

Gale, E. A. M. .

DIABETOLOGIA, 2009, 52 (09) :1766-1777

[35] Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin [J].

De Jonghe, Sandra ;

Proctor, Jim ;

Vinken, Petra ;

Feyen, Bianca ;

Wynant, Inneke ;

Marien, Dirk ;

Geys, Helena ;

Mamidi, Rao N. V. S. ;

Johnson, Mark D. .

CHEMICO-BIOLOGICAL INTERACTIONS, 2014, 224 :1-12

[36] Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis [J].

DeCensi, Andrea ;

Puntoni, Matteo ;

Goodwin, Pamela ;

Cazzaniga, Massimiliano ;

Gennari, Alessandra ;

Bonanni, Bernardo ;

Gandini, Sara .

CANCER PREVENTION RESEARCH, 2010, 3 (11) :1451-1461

[37] Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling [J].

Ding, Ling ;

Chen, Xi ;

Zhang, Wenxin ;

Dai, Xiaoyang ;

Guo, Hongjie ;

Pan, Xiaohui ;

Xu, Yanjun ;

Feng, Jianguo ;

Yuan, Meng ;

Gao, Xiaomeng ;

Wang, Jian ;

Xu, Xiaqing ;

Li, Sicheng ;

Wu, Honghai ;

Cao, Ji ;

He, Qiaojun ;

Yang, Bo .

JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (01)

[38] Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance [J].

Dore, David D. ;

Seeger, John D. ;

Chan, K. Arnold .

THERAPEUTIC ADVANCES IN DRUG SAFETY, 2012, 3 (04) :157-164

[39] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[40] Insulin glargine and risk of cancer: a meta-analysis [J].

Du, Xinli ;

Zhang, Rihua ;

Xue, Yi ;

Li, Dong ;

Cai, Jinmei ;

Zhou, Suming ;

Huang, Zhengkai ;

Yu, Rongbin ;

Liu, Yun .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2012, 27 (03) :241-246

← 1 2 3 4 5 6 7 8 9 10 →